Key Points
- CEO Richard Nolan Townsend has been selling shares recently — he sold 13,133 shares on Oct 17 (~$117,409) and 1,127 shares on Nov 18 (~$10,447), a transaction that reduced his stake by about 0.47%; he still directly owns 240,991 shares (~$2.23M).
- Lexeo shares trade around $9.14 (1‑year range $1.45–$10.38) with a market cap of about $667M; analysts' consensus is a Moderate Buy with a $18.63 target, and the company recently topped EPS estimates (-$0.33 vs. -$0.48).
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 1,127 shares of the firm's stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $9.27, for a total value of $10,447.29. Following the completion of the transaction, the chief executive officer directly owned 240,991 shares of the company's stock, valued at $2,233,986.57. The trade was a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Richard Nolan Townsend also recently made the following trade(s):
- On Friday, October 17th, Richard Nolan Townsend sold 13,133 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $8.94, for a total value of $117,409.02.
Lexeo Therapeutics Price Performance
Lexeo Therapeutics stock traded up $0.23 during trading hours on Friday, hitting $9.14. The stock had a trading volume of 367,717 shares, compared to its average volume of 786,510. Lexeo Therapeutics, Inc. has a 1-year low of $1.45 and a 1-year high of $10.38. The stock has a market capitalization of $666.98 million, a price-to-earnings ratio of -3.40 and a beta of 1.75. The stock's fifty day moving average is $7.96 and its two-hundred day moving average is $5.44.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.15. As a group, sell-side analysts anticipate that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. CWM LLC grew its position in shares of Lexeo Therapeutics by 150.3% in the second quarter. CWM LLC now owns 10,351 shares of the company's stock valued at $42,000 after purchasing an additional 6,216 shares during the period. Ethic Inc. purchased a new position in Lexeo Therapeutics during the second quarter worth about $44,000. Cerity Partners LLC acquired a new stake in Lexeo Therapeutics in the 2nd quarter worth about $50,000. Intech Investment Management LLC boosted its stake in Lexeo Therapeutics by 20.7% in the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company's stock worth $55,000 after buying an additional 2,342 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in Lexeo Therapeutics in the 2nd quarter valued at about $60,000. Hedge funds and other institutional investors own 60.67% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on LXEO. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. Chardan Capital reaffirmed a "buy" rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, November 5th. HC Wainwright reissued a "buy" rating on shares of Lexeo Therapeutics in a research report on Monday, November 3rd. Guggenheim assumed coverage on Lexeo Therapeutics in a report on Wednesday, October 15th. They issued a "buy" rating and a $30.00 price target for the company. Finally, Cantor Fitzgerald initiated coverage on Lexeo Therapeutics in a research note on Thursday. They set an "overweight" rating and a $19.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.63.
Get Our Latest Stock Report on Lexeo Therapeutics
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
